GV

TORONTO, April 10, 2026 (GLOBE NEWSWIRE) -- Visionary Holdings Inc. (NASDAQ:GV) ("Visionary" or the "Company") today announced that it received a notification letter dated April 7, 2026 from the Listing Qualifications Department of The Nasdaq Stock Market LLC ("Nasdaq"), indicating that the Company is not in compliance with the minimum bid price requirement set forth in Nasdaq Listing Rule 5550(a)(2) for continued listing on the Nasdaq Capital Market. According to the notification letter, the closing bid price of the Company's common shares was below US$1.00 per share for 30 consecutive business days, from February 23, 2026 to April 6, 2026. The notification has no immediate effect on th

TORONTO, April 07, 2026 (GLOBE NEWSWIRE) -- Visionary Holdings Inc. (NASDAQ:GV) (the "Company") today announced that it received a notification letter (the "Deficiency Letter") from the Nasdaq Listing Qualifications Department on April 2, 2026, indicating that the Company is not in compliance with the continued listing requirements set forth in Nasdaq Listing Rule 5250(c)(1). As described in the Deficiency Letter, the Company has not timely filed a Form 6-K containing its interim financial statements, including an unaudited balance sheet and income statement as of the end of its second fiscal quarter (the "Required Filing"). As a result, the Company is not currently in compliance with Nas

TORONTO, March 31, 2026 (GLOBE NEWSWIRE) -- Visionary Holdings Inc. (NASDAQ:GV) ("Visionary" or the "Company") today announced that it has entered into an Investment Cooperation Agreement with Qingdao Xihai Rongke Enterprise Operation Management Co., Ltd. in connection with a proposed US$20 million strategic investment for the Company's Qingdao anti-aging project in Qingdao West Coast New Area, China. Under the agreement, the parties plan to establish a project company to serve as the operating entity for the collaboration. The project company is expected to establish the "GV China Anti-Aging Research Center" in Qingdao West Coast New Area, with an initial focus on research and translatio

HONG KONG, March 26, 2026 (GLOBE NEWSWIRE) -- Visionary Holdings Inc. (NASDAQ:GV) (the "Company" or "Visionary") , a technology-driven multinational enterprise focused on biotechnology and healthcare, today announced that it has entered into a strategic cooperation agreement with Zhejiang Chushanji Digital Technology Co., Ltd. ("Chushanji"), a China-based enterprise engaged in digital marketing, brand services, and offline network operations. According to information provided by Chushanji, the company currently operates an extensive offline commercial network spanning 5 provinces and 105 district- and county-level markets in China, covering nearly 10,000 stores. Pursuant to the agreement

HONG KONG, March 09, 2026 (GLOBE NEWSWIRE) -- Visionary Holdings Inc. (NASDAQ:GV) ("the Company"), a technology-driven multinational enterprise focused on biotechnology and healthcare, today announced that its wholly owned subsidiary, Visionary Health Technology Group Limited ("GV Hong Kong"), has signed a US$12 million exclusive distribution agreement for its flagship anti-aging product, Premier Regenerative Complex-President Super Injection, in cooperation with Huajin China Investment Company（"Huajin China"), alongside the Board-approved divestiture of its non-core business. These strategic actions mark the Company's formal transition into a commercialization acceleration phase within t

HONG KONG, March 05, 2026 (GLOBE NEWSWIRE) -- Visionary Holdings Inc. (NASDAQ:GV) ("Visionary" or the "Company"), a technology-driven multinational enterprise focused on healthcare services, medical aesthetics, and advanced biotechnology applications, today provided its 2026–2027 business outlook and strategic growth priorities as the Company continues executing its expansion into global healthcare and medical aesthetics markets. Over the past year, Visionary has progressively repositioned its strategic focus toward higher-margin healthcare services and medical aesthetics businesses. The Company has previously announced initiatives aimed at expanding into international healthcare markets,

HONG KONG, March 02, 2026 (GLOBE NEWSWIRE) -- Visionary Holdings Inc. (NASDAQ:GV) ("the Company"), a technology-driven multinational and biotechnology and healthcare-focused company, today announced that its wholly owned subsidiary, Visionary Health Technology Group Limited ("GV Hong Kong"), today announced the signing of a US$12 million exclusive distribution agreement for its flagship anti-aging product, Premier Regenerative Complex---President Super Injection, in cooperation with Huajin China Investment Company（"Huajin China"), alongside the Board-approved divestiture of its non-core education business. These strategic actions mark the Company's formal transition into a commercializati

HONG KONG, Feb. 24, 2026 (GLOBE NEWSWIRE) -- Visionary Holdings Inc. (NASDAQ:GV) ("the Company"), a technology-driven multinational enterprise, today announced that its wholly owned subsidiary, Visionary Health Technology Group Limited ("GV Hong Kong"), continued execution progress under its previously signed commercial sales agreement with a total contract value of approximately US$9 million. The agreement, signed in September 2025, is currently in the implementation stage, with service activities underway. GV Hong Kong is working closely with its business partner to advance phased implementation efforts under the terms of the agreement. Execution UpdateSince the signing of the agreemen

HONG KONG, Feb. 18, 2026 (GLOBE NEWSWIRE) -- Visionary Holdings Inc. ("GV" or the "Company") (NASDAQ:GV), a technology-driven multinational enterprise, today announced that its wholly owned subsidiary, Visionary Health Technology Group Limited, has established three new regional wholly owned subsidiaries in Qingdao, Wuxi and Wuhu, China. These subsidiaries are primarily dedicated to localized market expansion, institutional partnerships, and frontline sales execution for GV's regenerative medicine, cellular rejuvenation, and aesthetic treatment product portfolio. This development represents a meaningful operational milestone in GV's transition from strategic platform buildout to coordina

TORONTO, Feb. 13, 2026 (GLOBE NEWSWIRE) -- Visionary Holdings Inc. (NASDAQ:GV) ("Visionary" or the "Company") announced today that in December 2025 it entered into a securities purchase agreement with an existing institutional investor (the "Investor"). In connection with the transaction, the Company issued to the Investor a senior secured convertible promissory note in the principal amount of $500,000 (the "December 2025 Note") in exchange for gross proceeds of $450,000. As previously disclosed, on January 31, 2025, the Company issued to the Investor a senior secured convertible promissory note in the principal amount of $1,500,000 (the "January 2025 Note") pursuant to a securities purch

MARKHAM, Ontario, Feb. 04, 2026 (GLOBE NEWSWIRE) -- Visionary Holdings Inc. (NASDAQ:GV) (the "Company"), a high-growth technology company specializing in innovative software solutions for the aesthetic medicine industry and cutting-edge advancements in stem cell research, today announced that it has received two formal communications from the Listing Qualifications Department of The Nasdaq Stock Market LLC ("Nasdaq") relating to the Company's periodic reporting status. On January 27, 2026, the Company received a Staff Determination Letter from Nasdaq indicating that the Company was not in compliance with Nasdaq Listing Rule 5250(c)(1) due to the delayed filing of its Annual Report on Form

TORONTO, Feb. 02, 2026 (GLOBE NEWSWIRE) -- Visionary Holdings Inc. ("GV" or the "Company"), a technology-driven multinational enterprise listed on Nasdaq (NASDAQ:GV), today announced that the Company has regained compliance with Nasdaq Listing Rule 5250(c)(1) in connection with the filing of its Annual Report on Form 20-F for the fiscal year ended March 31, 2025. As previously disclosed, on August 5, 2025, the Company was notified by Nasdaq that it was not in compliance with the periodic filing requirement under Nasdaq Listing Rule 5250(c)(1) due to the delayed filing of its Annual Report on Form 20-F for the fiscal year ended March 31, 2025. Based on the Company's filing of its Form 20-

6-K - Visionary Holdings Inc. (0001892274) (Filer)

20-F - Visionary Holdings Inc. (0001892274) (Filer)

TORONTO, Jan. 20, 2026 (GLOBE NEWSWIRE) -- In a release issued under the headline "CORRECTION – Visionary Holdings Inc." on Tuesday, January 13th by Visionary Holdings Inc. (NASDAQ:GV), please be advised there was an error in the attached Form 20-F PDF. The corrected release with the corrected attachment follows: Visionary Holdings Inc. Releases Final Fiscal Year 2025 Annual Report and Audited Financial Statements; Form 20-F Filing Pending  Highlighting Strategic Transformation and Early Commercial Progress in Emerging Health Businesses Visionary Holdings Inc. (NASDAQ:GV) (the "Company") today announced the public release of its final annual report and audited financial statements for t

TORONTO, Jan. 13, 2026 (GLOBE NEWSWIRE) -- In a release issued under the headline "Visionary Holdings Inc. Reports Fiscal Year 2025 Annual Report" on Monday, January 12th by Visionary Holdings Inc. (NASDAQ:GV), please be advised that the headline and content have been updated to accurately reflect comments from the U.S. Securities and Exchange Commission. The corrected release follows: Visionary Holdings Inc. Releases Final Fiscal Year 2025 Annual Report and Audited Financial Statements; Form 20-F Filing Pending  Highlighting Strategic Transformation and Early Commercial Progress in Emerging Health Businesses Visionary Holdings Inc. (NASDAQ:GV) (the "Company") today announced the public

TORONTO, Jan. 12, 2026 (GLOBE NEWSWIRE) -- Visionary Holdings Inc. (NASDAQ:GV) (the "Company") today announced the disclosure of its Annual Report on Form 20-F for the fiscal year ended March 31, 2025, outlining the Company's strategic transformation, business restructuring progress, and financial performance. During the reporting period, the Company continued to advance its transition from a traditional education- and real estate-focused business toward a diversified platform centered on health management, anti-aging and premium medical aesthetics, complemented by its AI-enabled education business. Emerging health-related businesses generated initial revenue contributions during the fisc

MARKHAM, Ontario, Dec. 30, 2025 (GLOBE NEWSWIRE) -- Visionary Holdings Inc. (the "Company"), today announced several material corporate developments, including the results of its 2025 Annual General Meeting, the formation of a new leadership team, and a formal strategic shift toward the anti-aging high-end medical aesthetics sector. A copy of the company's Report on Form-6K is being provided as an exhibit to this press release for reference. New Governance and Leadership TeamFollowing the Annual General Meeting held on October 29, 2025, a new nine-member Board of Directors was elected. The Board subsequently appointed a seasoned executive team to lead the Company's next phase of growth: E

HONG KONG, Dec. 30, 2025 (GLOBE NEWSWIRE) -- Visionary Holdings Inc. ("GV" or the "Company"), a technology-driven multinational enterprise listed on Nasdaq (NASDAQ:GV), today announced that its wholly owned subsidiary, Visionary Health Technology Group Limited（"GV Hong Kong"）, has official appointed Ms. Wenxuan Cai as Chief Executive Officer of GV Hong Kong, effective immediately. In parallel, the GV Hong Kong has established a new wholly owned subsidiary in Nanjing, China, dedicated primarily to sales execution and market development. This milestone marks GV's formal transition from strategic positioning to active on-the-ground revenue generation. Strengthening Leadership to Drive Marke

HONG KONG, Nov. 10, 2025 /PRNewswire/ -- Visionary Holdings Inc. ("GV" or the "Company"), a technology-driven multinational enterprise listed on Nasdaq (NASDAQ:GV), today announced that its wholly owned subsidiary, Visionary Health Technology Group Limited, has official launch of its medical-grade stem cell anti-aging product line, initially targeting the Chinese mainland and broader Asian markets. This launch marks a major milestone following GV's entry into the stem cell and medical aesthetics sector earlier this year, as well as its strategic partnership and global technology licensing agreement with Jiangsu Yike Regenerative Medicine Co., Ltd. ("Yike"), advancing the Company's commercia

TORONTO, Nov. 4, 2025 /PRNewswire/ -- At 10:00 a.m. (Eastern Time, USA) on November 3, 2025, Visionary Holdings Inc. ((hereinafter referred to as the ", Company", , NASDAQ:GV) successfully convened the First Meeting of the Fourth Board of Directors. In strict compliance with the Business Corporations Act (Ontario, 1990), Securities Exchange Act of 1934 (USA), NASDAQ Listing Rules, and the relevant provisions of the Company's Bylaws, the meeting was conducted with legitimate convening procedures, qualified participants, and rigorous voting rules. All directors attended the meeting and unanimously adopted all core proposals, with the resolutions being legally valid, laying a solid institutiona

TORONTO, Oct. 31, 2025 /PRNewswire/ -- Visionary Holdings Inc. (hereinafter referred to as the "Company"; a diversified enterprise registered in Ontario, Canada and listed on the Nasdaq Capital Market under the ticker symbol: GV) successfully held its 2025 Annual General Meeting (AGM) via Zoom video conference from 10:00 a.m. to 12:00 p.m. ET (UTC-4) on the same day. Chaired by Mr. Robert Jay LEES, the voting rights represented by attending shareholders and their proxies accounted for 97.79% of the company's total voting rights, far exceeding the quorum requirements stipulated in the Business Corporations Act (Ontario, 1990), Nasdaq Listing Rules, and the company's Articles of Association. T

TORONTO, Oct. 25, 2025 /PRNewswire/ -- Visionary Holdings Inc. (NASDAQ:GV) ("Visionary" or the "Company"), a private education service provider integrating technology and innovation, today announced that on August 5, 2025, it received a notification letter from the Listing Qualifications Department of The Nasdaq Stock Market ("Nasdaq") indicating that the Company is not in compliance with Nasdaq Listing Rule 5250(c)(1) due to its delay in filing its Annual Report on Form 20-F for the fiscal year ended March 31, 2025 (the "Form 20-F"). The Nasdaq letter has no immediate effect on the listing or trading of the Company's common shares on the Nasdaq Capital Market. In accordance with Nasdaq rul

TORONTO, Oct. 22, 2025 /PRNewswire/ -- Visionary Holdings Inc. ("GV" or the "Company"), a technology-driven multinational enterprise listed on Nasdaq (NASDAQ:GV), today announced the signing of a strategic cooperation agreement with Jiangsu Yike Regenerative Medical Technology Co., Ltd. ("Yike") to jointly establish Visionary Yike Stemcell Technologies Inc., a Canada-based joint venture dedicated to advancing stem cell research, clinical application, and commercialization worldwide. Under the agreement, GV and Yike will leverage their respective strengths in global commercialization and regenerative medicine with the goal of advancing the development of stem cell manufacturing and R&D hub i

TORONTO, Oct. 17, 2025 /PRNewswire/ -- Visionary Holdings Inc. (NASDAQ:GV, hereinafter referred to as ", Visionary", or the ", Company", )), a Nasdaq-listed enterprise, announced today that it has completed the equity adjustment of "Sikang (Guangzhou) Health Industry Investment Co., Ltd." (hereinafter referred to as the "Joint Venture Company"), a joint venture established with Guangzhou Sikang Investment Holding Co., Ltd. (hereinafter referred to as "Guangzhou Sikang"), and officially obtained a 51% equity stake to take control of the Joint Venture Company. This transaction marks a key step in Visionary's strategy of "global high-quality industry investment," aiming to leverage the synergy